Showing 9601-9610 of 20328 results for "".
- Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patientshttps://reachmd.com/news/influenza-vaccination-and-cardiovascular-outcomes-in-high-risk-patients/2486818/Key Takeaways Influenza vaccination was associated with lower all-cause mortality and lower cardiovascular mortality in patients with ischemic heart disease or heart failure. Myocardial infarction risk was lower in vaccinated patients, whereas stroke a
- Rapid Blood Infection Test Fails To Improve Survivalhttps://reachmd.com/news/rapid-blood-infection-test-fails-to-improve-survival/2486815/Key Takeaways Rapid testing was not superior to standard susceptibility testing for 30-day clinical outcomes, including mortality, in gram-negative bloodstream infection. Faster overall antibiotic escalation or de-escalation was observed, along with mo
- Imaging Bests Exam in Detecting Nodal Metastases in High-Risk cSCChttps://reachmd.com/news/imaging-bests-exam-in-detecting-nodal-metastases-in-high-risk-cscc/2486802/Ultrasonography and computed tomography (CT) outperformed physical examination for detecting baseline nodal metastases in high-risk cutaneous squamous cell carcinoma (cSCC). Investigators for the prospective, multicenter diagnostic study evaluated baseline staging modalities for detecting
- Vixarelimab Trial Reports Itch and Lesion Benefit in Prurigo Nodularishttps://reachmd.com/news/vixarelimab-trial-reports-itch-and-lesion-benefit-in-prurigo-nodularis/2486772/Key Takeaways Greater week 16 itch reduction was observed with vixarelimab than placebo, with the clearest effects in the 540-mg and 360-mg groups. Clinically meaningful WI-NRS responder rates and PN-IGA clear or almost clear responses were higher with
- AACR Release Highlights Pathomics Model For NSCLC Immunotherapy Responsehttps://reachmd.com/news/aacr-release-highlights-pathomics-model-for-nsclc-immunotherapy-response/2486773/Key Takeaways Path-IO applied to routine pathology slides in metastatic NSCLC was reported to separate patients into higher- and lower-risk groups with different outcomes. Investigators observed stronger discrimination than PD-L1 in both discovery and
- CDC Reports Interim 2025-26 Influenza Vaccine Effectivenesshttps://reachmd.com/news/cdc-reports-interim-2025-26-influenza-vaccine-effectiveness/2486778/Key Takeaways Vaccination was associated with reduced risk for influenza-associated outpatient visits and hospitalization, with higher overall estimates in children and adolescents than in adults. Reported protection included influenza A(H3N2) and infl
- POINTER Imaging Study Links Brain Biomarkers, Cognitive Benefithttps://reachmd.com/news/pointer-imaging-study-links-brain-biomarkers-cognitive-benefit/2486780/Key Takeaways No overall intervention-group differences were observed in longitudinal cognitive or imaging outcomes. Aβ status and Aβ accumulation were not associated with intervention-group differences and did not moderate them. In the struct
- Atacicept Reduced Proteinuria in Phase 3 IgA Nephropathy Trialhttps://reachmd.com/news/atacicept-reduced-proteinuria-in-phase-3-iga-nephropathy-trial/2486785/Key Takeaways At week 36, proteinuria declined more with atacicept than with placebo in the prespecified interim phase 3 readout. ORIGIN 3 is an ongoing randomized, double-blind, placebo-controlled phase 3 trial with 1:1 assignment and weekly subcutane
- Atezolizumab Plus FOLFOX Improves DFS in Stage III dMMR Colon Cancerhttps://reachmd.com/news/atezolizumab-plus-folfox-improves-dfs-in-stage-iii-dmmr-colon-cancer/2486784/Key Takeaways The phase 3 randomized trial compared atezolizumab plus mFOLFOX6 with mFOLFOX6 alone after resection in stage III dMMR colon cancer. Disease-free survival was higher and recurrence or death was lower with the atezolizumab-containing regim
- Smart Inhaler Feedback In Children With Uncontrolled Asthmahttps://reachmd.com/news/smart-inhaler-feedback-in-children-with-uncontrolled-asthma/2486786/Key Takeaways Several asthma control measures improved over time, but no significant between-group difference was observed. The intervention compared Respiro app-based reminders and personalized inhalation feedback with monitoring without feedback in c